Dividends Inside 
Banco Santander S.A. Sponsored ADR
SAN
$13.95 (+ $0.14 + 1.01%)
Last updated: 2026-07-04 02:46 UTC
Banco Santander S.A. Sponsored ADR trades under ticker SAN on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Financial Services exposure. Identifiers: ISIN US05964H1059, CUSIP 05964H105.
About the Company
Banco Santander S.A. Sponsored ADR represents ownership in Banco Santander S.A., a global financial services group headquartered in Madrid, Spain. The ADR structure allows U.S. investors to access the company’s ordinary shares through a U.S.-traded instrument, with each American depositary receipt corresponding to one underlying Banco Santander share. Banco Santander today operates as a diversified banking and financial services provider, focusing on retail and commercial banking, consumer finance, wealth management, and corporate and investment banking across Europe and the Americas. The group serves individuals, small and medium-sized enterprises, large corporates, and institutional clients with products such as deposits, loans, payment services, mortgages, insurance, and investment solutions. With a particularly strong presence in Spain and Latin America, Banco Santander S.A. Sponsored ADR plays a significant role in giving international investors exposure to banking and credit trends in these markets, while reflecting the performance of one of Europe’s largest cross-border banking groups.
Price History
Latest News for SAN
Regional REIT Q4 Earnings Call Highlights
Regional REIT (LON:RGL) executives told investors its 2025 full-year performance was shaped by a challenging operating backdrop and a slower-than-expected leasing market, but said the company made progress on key strategic priorities including asset sales, refinancing, and portfolio repositioning.
Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum
Sanofi has secured global exclusive rights to Kali Therapeutics' trispecific antibody KT501 for autoimmune diseases, including a first in human program for rheumatoid arthritis. The company has also received Japanese approval for Dupixent in bullous pemphigoid, making it the first targeted therapy for this condition in Japan. These two developments come as Sanofi, ticker ENXTPA:SAN, trades around €77.77, with the share price showing a 1.1% return over the past week and a 13.0% return over...
Linea Energy Closes Project Debt Financing for Watertown Solar in Michigan
Linea Energy ("Linea"), a U.S. based renewable energy developer and independent power producer ("IPP"), that is sponsored by EnCap Investments L.P. ("EnCap"), announced today that it has closed project financing for its Watertown solar project ("Watertown"). Watertown is a 172 MWdc utility-scale solar energy facility located in Sanilac County, Michigan.
Doral Renewables Secures Nearly $900 Million of Financing Commitments for Construction of Cold Creek Solar + Storage Project
Doral Renewables LLC ("Doral"), a leading, U.S. utility-scale solar and battery storage developer and independent power producer, announced today the successful financial close for the Cold Creek Solar + Storage project in Schleicher and Tom Green Counties in Texas.
Press release: Availability of the Q1 2026 aide-mémoire
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q1 2026 results will be published on April 23, 2026. About Sanofi Sanofi is an R
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,